Ustekinumab: An evidence-based review of its effectiveness in the treatment of psoriasis

Core Evidence

Volumn 5, Issue , 2010, Pages 11-22

  Krulig, Eliana ^a   Gordon, Kenneth B ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Biologics; Evidence; IL 12 23; Interleukin 12 (IL 12); Interleukin 23 (IL 23); Psoriasis; Ustekinumab

Indexed keywords

ADALIMUMAB; ALEFACEPT; BRIAKINUMAB; CALCIPOTRIOL; CD1C ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; DRUG ANTIBODY; EFALIZUMAB; ETANERCEPT; ETRETIN; GLYCOPROTEIN P 15095; HYDROXYUREA; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 22; INTERLEUKIN 23; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; PSORALEN; RETINOID DERIVATIVE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TAR; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; VITAMIN D DERIVATIVE;

ANAPHYLAXIS; ARTHRALGIA; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFECTION; INJECTION SITE REACTION; KERATINOCYTE; LOADING DRUG DOSE; LYMPHOCYTOPENIA; NEOPLASM; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHOTOTHERAPY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; QUALITY OF LIFE INDEX; REGULATORY T LYMPHOCYTE; REVIEW; RHINOPHARYNGITIS; SERUM SICKNESS; SIDE EFFECT; SKIN IRRITATION; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 79959349662     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-1912.
2. van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol. 2006;20:639-650.
3. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648-651. (Pubitemid 46232884)
4. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007;57:1059-1068.
5. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573-577. (Pubitemid 41399922)
6. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68-73. (Pubitemid 46934281)
7. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571-1575.
8. Nijsten T, Wakkee M. Complexity of the association of between psoriasis and comorbidities. J Invest Dermatol. 2009;129:1601-1603.
9. Gupta MA, Gupta AK. Depresion and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846-850. (Pubitemid 28520293)
10. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45:155-159; quiz 160-161.
11. Magin PJ, Pond CD, Smith WT, Watson AB, Goode SM. A cross-sectional study of psychological morbidity in patients with acne, psoriasis and atopic dermatitis in specialist dermatology and general practices. J Eur Acad Dermatol Venereol. 2008;22:1435-1444.
12. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284.
13. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153:486-497. (Pubitemid 41248202)
14. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407. (Pubitemid 29418506)
15. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78:827-851.
16. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850. (Pubitemid 351509656)
17. Krueger G, Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94-S100. (Pubitemid 40828186)
18. Somani AK, Yang MF, Cooper KD, McCormick TS. Cytokines and psoriasis. When cytokines become "pathokines". G Ital Dermatol Venereol. 2007;142:679-690.
19. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13:242-244. (Pubitemid 46376653)
20. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007;247:1-11. (Pubitemid 47464175)
21. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183-3194.
22. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol. 2007;119:1210-1217. (Pubitemid 46654193)
23. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol. 2009;129:302-308.
24. Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33:45-56. (Pubitemid 351514147)
25. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol. 2007;25:568-573. (Pubitemid 350103656)
26. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177:4917-4926. (Pubitemid 44469828)
27. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128:1653-1661. (Pubitemid 351847381)
28. Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol. 2008;47:1019-1023.
29. Gordon KB. Clinical Outcomes Measurements. In Gordon KB, Ruderman EM, eds. Psoriasis and Psoriatic Arthritis, An Integral Approach. New York: Springer; 2005:125-128.
30. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563-569. (Pubitemid 39278075)
31. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284. (Pubitemid 47071926)
32. Strowd LC, Yentzer BA, Fleischer AB Jr, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2008;60:478-481.
33. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009-1016.
34. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol. 2003;121:252-258. (Pubitemid 36969897)
35. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol. 2006;33:1442-1446. (Pubitemid 44025167)
36. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-864. (Pubitemid 351509657)
37. FDA Medwatch for Efalizumab. Feb 2009. URL: www.fda.gov
38. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416-430. (Pubitemid 38316135)
39. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52:434-444.
40. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res. 2006;298:7-15. (Pubitemid 43725207)
41. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-592. (Pubitemid 46220818)
42. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674. (Pubitemid 351671883)
43. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684. (Pubitemid 351671884)
44. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144:200-207. (Pubitemid 351287002)
45. Kim M, Min S, Cho M, et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:175-181. (Pubitemid 30064607)
46. Szodoray P, Alex P, Chapell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiple cytokine array system. Rheumatology. 2007;46:417-425. (Pubitemid 46344652)
47. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40.
48. Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust. 2003;179:438-440. (Pubitemid 37328013)
49. Tzu J, Krulig E, Cardenas V, Kerdel FA. Biological agents in the treatment of psoriasis. G Ital Dermatol Venereol. 2008;143:315-327.
50. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:274-285. (Pubitemid 352009861)
51. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727. (Pubitemid 36705938)
52. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606. (Pubitemid 44436647)
53. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115. (Pubitemid 350298146)
54. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312. (Pubitemid 40933433)
55. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29-35. (Pubitemid 43038667)
56. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374. (Pubitemid 41443403)
57. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol. 2004;16:393-398. (Pubitemid 38803140)